Galapagos NV (GLPG)

Compare

24.33

-0.17

(-0.71%)

As of 12:33:42 PM EDT. Market Open.

Biotech stocks slide as Marks resignation seen being negative for sector

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit

TipRanks 2 days ago

GLPG
-0.71%
GLPGF

PTCT
-3.25%
Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders’ Meeting

Mechelen, Belgium; March 27, 2025, 21:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2024 and announces its Annual Shareholders’ Meeting (AGM) to be held on Tuesday, April 29, 2025 at 14:00 CET at the registered office of the Company. The annual report for the financial year 2024, including a review of figures and performance, is available online at https://www.glpg.com/financial-reports and can also be downloaded a

GlobeNewswire 6 days ago

GLPG
-0.71%
GLPGF
Galapagos to Present at Upcoming Investor Conferences

Mechelen, Belgium; February 24, 2025, 22:01 CET – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced that its management will present at the following investor conferences in March:TD Cowen 45th Annual Healthcare Conference Date: Tuesday, March 4, 2025Location: Boston, MACorporate Presentation: 1:50 - 2:20 PM ET / 7:50 - 8:20 PM CETLive Webcast Link: HereBarclays 27th Annu

GlobeNewswire last month

GLPG
-0.71%
GLPGF
Galapagos (AMS:GLPG) adds €185m to market cap in the past 7 days, though investors from five years ago are still down 89%

Galapagos NV ( AMS:GLPG ) shareholders should be happy to see the share price up 13% in the last week. But will that...

Simply Wall St. last month

GLPG
-0.71%
GLPGF
Galapagos receives transparency notification and 13D filing from Tang Capital

Mechelen, Belgium; February 17, 2025, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification and 13D filing from Tang Capital. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on February 14, 2025 on behalf of Mr. Kevin Tang, Tang Capital Management, LLC (“TCM”), Tang Capital Partners, LP (“TCP”), Tang Capital Partners International, LP (“TCPI”), and Tang Capital Partners III, Inc. (“TCP III”), w

GlobeNewswire last month

GLPG
-0.71%
GLPGF
Galapagos NV (GLPG) (FY 2024) Earnings Call Highlights: Strategic Shifts and Financial Resilience

Galapagos NV (GLPG) reports strong financials and strategic advancements amid increased R&D expenses and operational restructuring.

GuruFocus.com last month

GLPG.AS
Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein Focusing on accelerating GLPG5101 program, expanding to eight indications with significant unmet needs, and aiming for first approval by 2028 Plan to separate into two companies listed on Nasdaq and Euronext, with SpinCo to build a pipeline through deals and Galapagos to advance novel cell therapies

GlobeNewswire last month

GLPG
-0.71%
GLPGF
Galapagos NV (GLPG): A Cheap Biotech Stock to Invest In Now

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at where Galapagos NV (NASDAQ:GLPG) stands against the other cheap biotech stocks. Biotech Stocks Face Uncertainty Despite Interest Rate Cuts Biotechnology stocks are among the most volatile in the market due […]

Insider Monkey last month

GLPG.AS
Galapagos (GLPG) Loses -21.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Galapagos (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks last month

GLPG.AS
Galapagos Plans to Split Into Two Entities, Revise Agreement With Gilead Sciences, Reduce Workforce by 40%

Galapagos (GLPG) said Wednesday that it plans to split into two entities, with a new company, or Spi

PREMIUM
MT Newswires 2 months ago

GILD

GLPG.AS
Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions Galapagos will gain full global development and commercialization rights to its pipeline, focusing on accelerating cell therapies and building a global, decentralized manufacturing network Galapagos to implement a strategic reorganization to position the Company for long-term growth and cell therapy leadership in oncolog

GlobeNewswire 2 months ago

GLPG
-0.71%
GLPGF
Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Mechelen, Belgium; January 7, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 pm PT in San Francisco.A live webcast of the presentation will be accessible on the Investors page of the Company’s website at www.glpg.com/investors. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.In ad

GlobeNewswire 2 months ago

GLPG
-0.71%
GLPGF
Galapagos NV (AMS:GLPG) stock most popular amongst retail investors who own 56%, while public companies hold 25%

Key Insights Galapagos' significant retail investors ownership suggests that the key decisions are influenced by...

Simply Wall St. 3 months ago

GLPG
-0.71%
GLPGF
ASH 2024: Galapagos presents positive results for a seven-day ‘vein-to-vein’ CAR T-cell therapy

This early data has demonstrated a clear improvement in GLPG5101 efficacy over its competitors in iNHL and MCL.

Clinical Trials Arena 3 months ago

GLPG.AS
$Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma$

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity and an encouraging safety profile in all NHL subtypes studied.96% of patients received an infusion of fresh, fit, stem-like, early memory CD19 CAR T-cell therapy with a median vein-to-vein time of seven days, avoiding the need for cryopreservation and bridging therapy.These data reinforce the potential of Galapagos’ decentralized cell therapy manufacturing platf

GlobeNewswire 3 months ago

GLPG
-0.71%
GLPGF
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

New Phase 1/2 data support the potential of our CAR T-cell therapy candidates, GLPG5101 and GLPG5201, in addressing unmet needs for patients with poor prognoses. Our innovative decentralized cell therapy manufacturing platform delivers fresh, fit cells within a median vein-to-vein time of seven days, with potentially encouraging patient outcomes. Three abstracts, including one oral presentation for GLPG5101 in relapsed/refractory non-Hodgkin lymphoma, and a company showcase, will spotlight our c

GlobeNewswire 4 months ago

GLPG
-0.71%
GLPGF
Galapagos Third Quarter 2024 Earnings: €0.74 loss per share (vs €0.39 profit in 3Q 2023)

Galapagos ( AMS:GLPG ) Third Quarter 2024 Results Key Financial Results Revenue: €59.8m (down 50% from 3Q 2023). Net...

Simply Wall St. 4 months ago

GLPG
-0.71%
GLPGF
Galapagos NV (GLPG) Q3 2024 Earnings Call Highlights: Strong Cash Position and R&D Progress ...

Galapagos NV (GLPG) reports a robust cash reserve and significant advancements in its R&D pipeline, while navigating increased R&D costs and competitive market pressures.

GuruFocus.com 4 months ago

GLPG.AS
Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

We are advancing our pipeline and accelerating innovation through focused execution of our Forward, Faster strategy.We are committed to addressing the high unmet needs of patients through a growing cell therapy and small molecule pipeline with breakthrough potential. This includes more than 20 programs, with four assets in clinical development across 11 indications, and more than 15 preclinical programs in oncology and immunology. We achieved a major regulatory milestone with the FDA clearance o

GlobeNewswire 4 months ago

GLPG
-0.71%
GLPGF
Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director to its Board of Directors, effective October 7, 2024. Mr. Nodelman replaces Mr. Dan G. Baker who stepped down on October 6, 2024. The addition of Mr. Nodelman marks an important step in Galapagos’ ongoing efforts to engage with shareholders and continue to execute on our Forward, Faster strategy to

GlobeNewswire 5 months ago

GLPG
-0.71%
GLPGF

Performance Overview

Return	GLPG	AEX-Index (^AEX)
YTD	-10.90%	-0.14%
1-Year	-23.43%	-0.75%
3-Year	-62.65%	+20.52%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Galapagos NV (GLPG)

Biotech stocks slide as Marks resignation seen being negative for sector

Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders’ Meeting

Galapagos to Present at Upcoming Investor Conferences

Galapagos (AMS:GLPG) adds €185m to market cap in the past 7 days, though investors from five years ago are still down 89%

Galapagos receives transparency notification and 13D filing from Tang Capital

Galapagos NV (GLPG) (FY 2024) Earnings Call Highlights: Strategic Shifts and Financial Resilience

Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

Galapagos NV (GLPG): A Cheap Biotech Stock to Invest In Now

Galapagos (GLPG) Loses -21.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Galapagos Plans to Split Into Two Entities, Revise Agreement With Gilead Sciences, Reduce Workforce by 40%

Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Galapagos NV (AMS:GLPG) stock most popular amongst retail investors who own 56%, while public companies hold 25%

ASH 2024: Galapagos presents positive results for a seven-day ‘vein-to-vein’ CAR T-cell therapy

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

Galapagos Third Quarter 2024 Earnings: €0.74 loss per share (vs €0.39 profit in 3Q 2023)

Galapagos NV (GLPG) Q3 2024 Earnings Call Highlights: Strong Cash Position and R&D Progress ...

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

Performance Overview